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Abstract 
Background: Oxidative stress and inflammation may be involved in the development and progression of mood 
disorders, including bipolar disorder. Currently, there is a scarcity of useful treatment options for bipolar depressive 
episodes, especially compared with the efficacy of treatment for acute mania. N-Acetylcysteine (NAC) has been 
explored for psychiatric disorders for some time given its antioxidant and anti-inflammatory properties. The current 
trial aims at testing the clinical effects of adjunctive NAC treatment (compared to placebo) for bipolar depression. 
We will also explore the biological effects of NAC in this context. We hypothesize that adjunctive NAC treatment will 
reduce symptoms of depression, which will be reflected by changes in selected markers of oxidative stress.
Methods and analysis: In the study, we will include adults diagnosed with bipolar disorder, in a currently depressive 
episode. Participants will undertake a 20-week, adjunctive, randomized, double-blinded, parallel group placebo-con-
trolled trial comparing 3 grams of adjunctive NAC daily with placebo. The primary outcome is the mean change over 
time from baseline to end of study on the Montgomery–Asberg Depression Rating Scale (MADRS). Among the sec-
ondary outcomes are mean changes from baseline to end of study on the Bech-Rafaelsen Melancholia Scale (MES), 
the Young Mania Rating Scale (YMRS), the WHO-Five Well-being Index (WHO-5), the Global Assessment of Function-
ing scale (GAF-F), the Global Assessment of Symptoms scale (GAF-S) and the Clinical Global Impression-Severity scale 
(CGI-S). The potential effects on oxidative stress by NAC treatment will be measured through urine and blood samples. 
DNA will be examined for potential polymorphisms related to oxidative defences.
Trial registration: Registered at The European Clinical Trials Database, ClinicalTrials.gov: NCT02294591 and The Danish 
Data Protection Agency: 2008-58-0035.
Keywords: Bipolar disorder, Depression, Acetylcysteine, Oxidative stress, Inflammation, Urine, Blood, Treatment, 
Psychiatry, Genetics
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Background
Bipolar disorder is generally characterized by recurrent 
episodes of mania (or hypomania) and major depression 
(Goodwin and Jamison 2007), with depressive phases 
being the dominant phase in terms of overall duration 
(Judd and Akiskal 2003).
In recent treatment guidelines for bipolar disorder, 
combinations of pharmacotherapy and psychotherapeuti-
cal treatments such as psychoeducation and individual or 
group-based psychotherapy are generally recommended 
(Fountoulakis et  al. 2017). Regarding pharmacotherapy, 
combined use of various drugs is often beneficial in terms 
of both acute treatment response and for maintenance 
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(Geddes et  al. 2016). However, despite all efforts, treat-
ment outcome is often inadequate, necessitating the 
development of new, more effective treatments. There a 
scarcity of effective treatments for the acute treatment of 
bipolar depression, in particular (Grunze et al. 2010).
Studies have indicated that oxidative stress and neuro-
inflammation seem to be linked to the pathophysiology of 
bipolar disorder (Andreazza et al. 2008; Berk et al. 2011). 
Recent studies have reported increased levels of oxidative 
stress markers in blood and urine samples from patients 
suffering from bipolar disorder (Andreazza et  al. 2007, 
2008; Munkholm et al. 2015; Jacoby et al. 2016). Further-
more, there is evidence that the level of oxidative stress 
may be a state marker in bipolar disorder (Munkholm 
et al. 2015; Fernandes et al. 2011; Polyakova et al. 2015).
The brain is thought to be especially vulnerable to oxi-
dative stress due to its’ high metabolic demands and its’ 
limited capacity of defences such as glutathione (GSH), 
which is the central antioxidant in all tissues (Ballatori 
et al. 2009). Bipolar disorder is associated with decreased 
GSH levels, resulting in increased oxidative stress 
(Andreazza et al. 2008; Rosa et al. 2014; Brown et al. 2014; 
Soeiro-de-Souza et  al. 2013). N-Acetylcysteine (NAC), 
the acetyl derivative of the amino acid cysteine, improves 
the l-cysteine supply, which increases GSH levels in the 
brain (Choy et  al. 2010; Dean et  al. 2009). Accordingly, 
NAC treatment appears to decrease oxidative stress and 
inflammation (Dean et  al. 2011). Two previous clinical 
trials on NAC for bipolar disorder have shown significant 
effects on depressive symptoms (Berk et al. 2008, 2011).
Study rationale
Given the paucity of effective pharmacotherapy for bipo-
lar depression, it seems warranted to test whether the 
previous positive findings of NAC for bipolar depression 
can be replicated in a Danish study sample. Furthermore, 
we wanted to go further than these studies by exploring 
the antioxidant effects of NAC in the context of the clini-
cal trial. Finally, it would be useful for the development 
of new pharmacotherapies in general to test whether the 
potential antidepressant efficacy of NAC is linked to its 
antioxidant effects. In addition to the latter point, find-
ing a relationship between the level of oxidative stress at 
baseline and the efficacy of NAC would be a step towards 
the goal of precision psychiatry (Fernandes et al. 2017).
Aims and objectives
The primary aim is to investigate the effects of adjunctive 
NAC treatment on depressive symptoms in participants 
diagnosed with bipolar depression. The secondary aims 
are to measure the biological effect of NAC treatment 
based on markers of oxidative stress in urine samples.
The study objectives are following:
Process aim 1
Assessing baseline adjusted between-group mean change 
between NAC and placebo group from baseline up till 
week 20 on The Montgomery–Asberg Depression Rating 
Scale score (MADRS) (Montgomery and Åsberg 1979).
Process aim 2
Assessing baseline adjusted between-group mean dif-
ference between NAC and placebo group from base-
line up till week 20 on; the Bech-Rafaelsen Melancholia 
Scale (MES) (Bech 2002), the Young Mania Rating Scale 
(YMRS) (Young et  al. 1978), the WHO-Five Well-being 
Index (WHO-5) (Staehr 1998), the Global Assessment 
of Functioning scale (GAF-F), The Global Assessment of 
Symptoms scale (GAF-S) (Jones et al. 1995) and the Clin-
ical Global Impression-Severity scale (CGI-S) (Guy WNI-
oMHPRBECDEP 1976).
Process aim 3
Assessing baseline adjusted between-group mean differ-
ence between NAC and placebo group from baseline up 
till week 20 in urine samples to explore biological correla-
tion in DNA and RNA damage by oxidative stress.
Process aim 4
Assessing baseline adjusted between-group mean differ-
ence between NAC and placebo group from baseline up 
till week 24 on MADRS, MES, YMRS, WHO-5, GAF-F, 
GAF-S, CGI-S and urinary markers.
Process aim 5
Assessing baseline urinary markers to explore correla-
tion in DNA and RNA damage by oxidative stress and the 
degree of depression severity.
Additionally, blood samples and DNA are collected for 
further explorations towards detecting potential genetic 
polymorphisms related to oxidative defences, but are 
currently stored.
Methods
Trial design
This is a 20-week randomized, double-blind, paral-
lel group, placebo-controlled, multicentre trial, with a 
4-weeks follow up after study treatment discontinuation. 
The protocol is developed in accordance with the Stand-
ard Protocol Items: Recommendations for Intervention 
Trials (SPIRIT) 2013 Guidelines (Chan et  al. 2013). The 
study will follow the Consolidated Standards of Report-
ing Trials (CONSORT) guidelines to describe, report and 
publish the results (Schulz et al. 2010).
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Visits and telephone calls
The study visits (outlined in Fig. 1) are planned to be at 
week 2, 10, 20 and 24 (± 7 days for each visit). Further-
more, participants will be contacted via telephone 6 and 
15 weeks after inclusion (± 7 days). Telephone calls are 
conducted with participants to support adherence and 
provide an opportunity for participants to discuss any 
issues with the study (including adverse events).
Participant selection
The study participants will be recruited amongst in-and 
out patients from the Mental Health Services from three 
study centres covering three geographical areas (three cit-
ies in centre one and two, and one city in centre three). We 
plan to recruit participants over a study period of 2 years.
Participants assess for eligibility will be screened 
according to the inclusion and exclusion criteria.
Participant eligibility
Inclusion criteria
Participants will be included if they meet all of the fol-
lowing criteria:
  • 18–64 years of age at baseline (inclusive).
  • A diagnosis of bipolar disorder type I or II, current 
episode of depression according to Diagnostic and 
Statistical Manual of Mental Disorders 5 (DSM-V) 
(American Psychiatric Association 2000) (evaluated 
by using the M.I.N.I (International Neuropsychiatric 
Interview), version 5.0 in Danish (Sheehan et al. 1998).
  • At least one documented affective episode within the 
last 6  months within the index period (depressive, 
manic or mixed), as judged by the principal investi-
gator (according to the medical journal, and clinical 
interview based on the M.I.N.I
  • Have had symptoms of depression for at least 
4 weeks up till screening, and a Montgomery–Asberg 
Depression Rating Scale (MADRS) score of ≥  18 
(mild depression or more) at that time.
  • Have given full oral and written informed consent.
Female participants should present a negative pregnant 
test at baseline and will be informed to use effective con-
traception throughout the study period.
Exclusion criteria
Participants will be excluded if they meet any of the fol-
lowing criteria:
  • Have a daily intake of more than 500  mg NAC, 
200 μM selenium, or 500 IU of vitamin E at screen-
ing.
  • Have received electroconvulsive therapy (ECT) 
within the last 4 weeks prior to screening.
  • Have epilepsy, chronic asthma or allergy towards 
NAC, as judged by investigator.
  • Involuntary admitted, detainment or treated accord-
ing to the statutes defined in the Mental Health Act.
  • Cannot speak or understand the Danish language.
  • Females planning pregnancy or breastfeeding during 
the timeframe of the study.
Discontinuation criteria
Participants will discontinue the study under the follow-
ing circumstances:
  • Withdrawal of consent.
  • Discontinues study treatment for 7 or more consecu-
tive days.
Screening
-M.I.N.I.-interview
-MADRS rang score
Baseline
(Week 0)
- Quesonaires
- Collecon of 
urine, blood and 
DNA
Visit 2
(Week 2)
- Quesonaires
- Collecon of 
urine
Call 1
(Week 6)
Visit 3
(Week 10)
- Quesonaires
- Collecon of 
urine
Call 2
(Week 15)
Visit 4
(Week 20)
- Quesonaires
- Collecon of 
urine, blood and 
DNA
Visit 5
(Week 24)
- Quesonaires
- Collecon of 
urine, blood and 
DNA
Fig. 1 Timeline with outcomes measures. M.I.N.I-interview Mini International Neuropsychiatric Interview, MADRS Montgomery–Asberg Depression 
Rating Scale
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  • Does not comply with the defined study visits (visits 
within 7 days prior or after the computer-generated 
date).
  • Becomes pregnant, initiates breastfeeding, or wishes 
to become pregnant during the study period.
  • Becomes hypersensitive to histamine, as judged by 
investigator.
  • Develops serious adverse reaction/event (SAR/SAE) 
i.e. suspected to be associated with the study treat-
ment, as judged by an investigator.
  • Stops using effective contraception.
  • Changes diagnosis during the study, and the primary 
diagnosis is no longer bipolar affective disorder.
  • Involuntary admitted, detainment or treated accord-
ing to the statutes defined in the Mental Health Act.
  • Becomes increasingly suicidal during the study as 
judged by investigator.
Randomization
Participants will be randomized to NAC or placebo treat-
ment by a computer-based random eight block number 
generator. The study participants will be randomised 
sequentially by the order they are enrolled into the trial. 
The randomization assignments will be hidden from the 
participants and the study investigators and raters. An 
independent pharmacy, Glostrup Pharmacy, will per-
form the randomization process, provide the randomiza-
tion codes and the labelling of the tablet containers. The 
Coordinating Investigator (PKE) and Sponsor/Principal 
Investigator (CTN) will enrol and assign participants 
from two of the study centres, and the second Principal 
Investigator (REN) and a project nurse (HOE) will enrol 
and assign participants from the latter study centre.
Blinding procedure
The study medication is blinded to both study partici-
pants and the investigators. If un-blinding of one or more 
study participants is required, Glostrup Pharmacy hold 
the randomization list and can be contacted 24 h a day. 
Furthermore, the investigators have a sealed envelope 
with the randomization list, if there is a need for un-
blinding of any participants. To minimize the risk of par-
ticipants comparing experiences, the study visits will be 
arranged staggered throughout the day and always sepa-
rately. When all study participants have completed the 
trial, the study medication will be un-blinded.
Study treatment
Participants will be randomized to receive either NAC 
(National Center for Biotechnology Information 2017) 
or placebo in addition to their current pharmacotherapy 
and psychotherapy.
The study treatment powder (NAC and placebo) are 
imported and manufactured at Glostrup Pharmacy, 
which has manufacturing authorization, and all medica-
tion used is manufactured in accordance with good man-
ufacturing practice (GMP) and good distribution practice 
(GDP).
The study medication is divided into nine, white con-
tainers containing 100 tablets each. The study medication 
is distributed twice during the 20  weeks, and receive 9 
containers in total.
Participants will take three tablets containing 500  mg 
each, twice daily (3 g daily) for 20 weeks. NAC and pla-
cebo tablets have a similar appearance and have an added 
lemon odour, in order to camouflage the sulphur-con-
taining odour of NAC.
ECT is not permitted 4 weeks prior to inclusion, but is 
allowed during the trial. Treating clinicians are allowed 
to change both psychopharmacy and psychotherapy dur-
ing the trial at their discretion.
Treatment adherence
To enhance adherence, the participants will be offered a 
text message with two daily reminder messages on taking 
the study medication. The participants will be encour-
aged to return all remaining trial medication at the end 
of study participation. The returned tablet containers and 
the tables will all be counted and documented.
Outcome measures
The clinical and demographic data is obtained by the 
investigators through patient interviews and from hospi-
tal records. The biological data is obtained through labo-
ratory analyses of blood and urine samples. An overview 
of the data collection process is displayed in Table 1.
Clinical outcome measures
The clinical measurements include scales of depres-
sive symptoms (MADRS and MES), manic symptoms 
(YMRS), quality of life (WHO-5), symptoms- and social 
functioning level (GAF-S and GAF-F) and global clinical 
impression (CGI-S). All rating scales used in the study 
are assessed and validated in Danish.
Biological outcome measures
The biological data collected from the study participants 
will include urine and blood samples as well as DNA. The 
biological data will be applied to investigate markers of 
oxidative stress and inflammation. All biological materi-
als (urine, blood and DNA) will be collected from not-
fasting participants. The urine and blood samples are 
transferred to tubes, and all three biological materials are 
stored in hospital freezers until analysis.
Page 5 of 9Ellegaard et al. Int J Bipolar Disord  (2018) 6:11 
Ta
b
le
 1
 O
ve
rv
ie
w
 o
f a
ll 
m
ea
su
re
m
en
ts
, i
n
st
ru
m
en
ts
 a
n
d
 ti
m
e 
p
o
in
ts
Sc
re
en
in
g 
p
re
-in
te
rv
en
tio
n,
 B
as
el
in
e 
p
re
-in
te
rv
en
tio
n 
(w
ee
k 
0)
, V
is
it 
2 
w
ee
k 
2,
 V
is
it 
3 
w
ee
k 
10
, V
is
it 
4 
p
os
t-
in
te
rv
en
tio
n 
(w
ee
k 
20
), 
Vi
si
t 5
 fo
llo
w
-u
p
 (w
ee
k 
24
), 
Ra
te
r c
oo
rd
in
at
in
g 
in
ve
st
ig
at
or
/p
ro
je
ct
 n
ur
se
, M
A
D
RS
 
M
on
tg
om
er
y-
Å
sb
er
g 
D
ep
re
ss
io
n 
Ra
tin
g 
Sc
al
e 
sc
or
e,
 M
ES
 B
ec
h-
Ra
fa
el
se
n 
M
el
an
ch
ol
ia
 S
ca
le
, W
H
O
-5
 W
or
ld
 H
ea
lt
h 
O
rg
an
iz
at
io
n 
w
el
l-b
ei
ng
 in
de
x,
 G
A
F-
S 
Th
e 
G
lo
b
al
 A
ss
es
sm
en
t o
f S
ym
p
to
m
s 
sc
al
e,
 G
A
F-
F 
Th
e 
G
lo
b
al
 
A
ss
es
sm
en
t o
f F
un
ct
io
ni
ng
 s
ca
le
, Y
M
RS
 Y
ou
ng
 M
an
ia
 R
at
in
g 
Sc
al
e 
(Y
M
RS
), 
CG
I-S
 T
he
 C
lin
ic
al
 G
lo
b
al
 Im
p
re
ss
io
n-
Se
ve
rit
y 
sc
al
e 
(C
G
I-I
), 
M
.I.
N
.I-
in
te
rv
ie
w
 M
in
i I
nt
er
na
tio
na
l N
eu
ro
p
sy
ch
ia
tr
ic
 In
te
rv
ie
w
, E
CT
 e
le
ct
ro
co
nv
ul
si
ve
 
th
er
ap
y
Va
ri
ab
le
s
So
ur
ce
s
St
ud
y 
p
er
io
d
En
ro
lm
en
t
In
te
rv
en
ti
on
Fo
llo
w
-u
p
Sc
re
en
in
g
B
as
el
in
e 
(w
ee
k 
0)
V
is
it
 2
 (w
ee
k 
2)
V
is
it
 3
 (w
ee
k 
10
)
V
is
it
 4
 (w
ee
k 
20
)
V
is
it
 5
 (w
ee
k 
24
)
M
A
D
RS
Ra
te
r
X
X
X
X
X
M
ES
, W
H
O
-5
, G
A
F-
S,
 G
A
F-
F, 
CG
I-S
 Y
M
RS
Ra
te
r/
se
lf-
re
po
rt
ed
X
X
X
X
X
M
.I.N
.I.-
In
te
rv
ie
w
Ra
te
r
X
D
em
og
ra
ph
ic
 (a
ge
, g
en
de
r, 
he
ig
ht
, i
nc
lu
si
on
 s
ite
, e
tc
.)
Se
lf-
re
po
rt
ed
X
W
ei
gh
t a
nd
 B
M
I
Ra
te
r
X
X
X
X
X
Pe
rs
on
al
 a
nd
 d
em
og
ra
ph
ic
 d
et
ai
ls
 (i
nc
om
e 
so
ur
ce
, e
du
-
ca
tio
n,
 re
la
tio
ns
hi
p 
et
c.
)
Se
lf-
re
po
rt
ed
X
Fa
m
ily
 m
en
ta
l h
is
to
ry
Se
lf-
re
po
rt
ed
X
Li
fe
st
yl
e 
in
fo
rm
at
io
n 
(s
m
ok
in
g 
st
at
us
, a
lc
oh
ol
 c
on
su
m
p-
tio
n 
an
d 
su
bs
ta
nc
e 
ab
us
e)
Se
lf-
re
po
rt
ed
X
X
X
X
X
D
is
or
de
r i
nf
or
m
at
io
n 
(n
o.
 o
f: 
ep
is
od
es
 o
f d
ep
re
ss
io
n,
 
hy
po
m
an
ia
/m
an
ia
, n
eu
tr
al
 m
oo
d,
 E
C
T,
 h
os
pi
ta
l a
dm
is
-
si
on
s, 
su
ic
id
al
 th
ou
gh
ts
, s
ui
ci
de
 a
tt
em
pt
s, 
et
c.
)
Se
lf-
re
po
rt
ed
/h
os
pi
ta
l r
ec
or
d
X
M
ed
ic
al
 c
on
di
tio
ns
 (D
oc
to
r d
ia
gn
os
ed
)
Se
lf-
re
po
rt
ed
X
Ph
ar
m
ac
ol
og
ic
al
 tr
ea
tm
en
t
H
os
pi
ta
l r
ec
or
d
X
X
X
X
X
Ps
yc
ho
lo
gi
ca
l t
re
at
m
en
t
Se
lf-
re
po
rt
ed
X
X
X
X
X
A
dv
er
se
 e
ve
nt
s/
re
ac
tio
ns
Se
lf-
re
po
rt
ed
X
X
X
X
X
Bi
og
ra
ph
y
Se
lf-
re
po
rt
ed
X
U
rin
e 
sa
m
pl
es
La
bo
ra
to
ry
X
X
X
X
X
Bl
oo
d 
sa
m
pl
es
La
bo
ra
to
ry
X
X
X
D
N
A
La
bo
ra
to
ry
X
X
X
Page 6 of 9Ellegaard et al. Int J Bipolar Disord  (2018) 6:11 
Serious adverse reactions/events and adverse reactions/
events
SARs, SAEs, Adverse Events (AE) and Adverse Reac-
tions (AR) are defined according to good clinical practice 
(GCP), and assessed at each visit. Participants who dis-
continue study participation due to SAEs or SARs will be 
followed until the SAE/SAR has disappeared or the SAE/
SAR is stable. Participants will be contacted with a few 
days after SAE/SAR and again after 4 weeks.
Data management
The trial is conducted in accordance with good clinical 
practice guidelines and Declaration of Helsinki, and will 
be monitoring by the GCP-unit at Odense University 
Hospital, Denmark. The study is approved before study 
initiation by the Regional Scientific Ethical Committees 
for Southern Denmark: 35664-20120177, the Danish 
Medicines Agency: 2012-004483-22, and Danish Data 
Protection Agency: 2008-58-0035. The trial is registered 
at ClinicalTrials.Gov: NCT02294591 and the European 
Clinical Trials Database, EudraCT: 2012-004483-22.
All data in the CRFs (Case Report Forms) are double 
entered in the database program Research Electronic 
Data Capture (REDCap) (Harris et  al. 2009) by coordi-
nating investigator (PKE).
Sample size and feasibility of recruitment
The sample size estimation was based on prior data from 
a similar clinical trial showing mean (SD) in MADRS 
score (from baseline to end of the study (week 24)) was 
decreased by around 10.0 ± 4.3 and increased by around 
0.9 ± 2.6 (in respectively the NAC and the placebo group 
(Berk et al. 2008). Our sample size was calculated using 
a two-tailed independent sample t-test with 80% power 
to detect baseline-adjusted between-group mean differ-
ence at week 20, and a two-sided alpha-level of 0.05. To 
detect a between-group mean difference of change from 
baseline of at least 8 ± 10.0, 56 participants in total were 
required. Due to the expectation of a 40% drop-out rate 
we aim to recruit an overall of 78 study participants. To 
achieve an adequate number of participants, all in- and 
out-patients from the Mental Health Service included in 
the study having a bipolar disorder or suspect to have this 
disorder, are offered to participate.
Statistical analysis plan
A statistical significant difference in mean change on 
MADRS-score, between study groups, from baseline 
to end of study, is the primary outcome measure of the 
study. The remaining clinical and biological measures 
are secondary outcome measures and will be analysed 
using the same approach as the primary outcome. To 
investigate the difference in response and remission 
rates between study treatments at week 20 and 24, 
logistic regression models will be applied to estimate 
the odds ratios. The definition of a “responder” is a per-
son which symptoms of depression has dropped 50% 
in MADRS-score from baseline to week 20 or 24, and 
“remitters” are defined as MADRS score <  10 (Haw-
ley et  al. 2002) at week 20 or 24. Data analysis will be 
conducted by the authors and a statistician. Between-
group comparisons will be performed by applying Stu-
dent t-tests, Mann–Whitney U tests, Chi square tests or 
Fishers exact test, whichever is most appropriate. The 
primary analysis for primary and secondary outcomes 
will be based on an Intention-To-Treat (ITT) analysis 
comprise all study participants completed the base-
line measurements. A generalized estimating equation 
(GEE) (Feng et al. 2001) approach will be taken, and the 
likelihood-based linear mixed effects repeated measures 
(LMERM) analyses (Mallinckrodt et al. 2001; Laird and 
Ware 1982) is the primary analysis. The LMERM-anal-
ysis includes the fixed variable study treatment, visits 
as factor variable, and treatment-by-visits interaction 
(intervention impact). The LMERM includes all availa-
ble data at each time point and is the preferred methods 
of analysing clinical trial data in psychiatry due to the 
fact that likelihood approach deals with missing data in 
follow-ups assuming missingness is at random. Planned 
comparisons will be done with the LMERM models to 
determine between-group differences in score change 
from baseline to week 2, week 10, week 20 and week 24. 
Additional per-protocol analysis includes participants 
who completed the study intervention. Sensitivity anal-
ysis will evaluate missing at random assumptions for 
missing follow-up data. Missing data will be imputed 
assuming Missing Not At Random (MNAR) in interven-
tion, control and both arms respectively and robustness 
of finding under different MNAR assumptions will be 
examined.
Additionally, effect sizes will be reported using Cohen’s 
guidelines (Cohen 1988). Dichotomous data will be pre-
sented as proportions, with 95% confidence interval, and 
reporting Chi square of Fishers’s exact p-value where 
appropriate. Likelihood based generalized linear mixed 
repeated measures approach (GLMRM) with logit link 
will be used to compare dichotomous outcomes.
All tests of treatment effects will be conducted using 
a two-sided alpha level of 0.05. The statistical analysis 
will be conducted utilizing the statistical software pro-
gram STATA IC, version 15 (StataCorp. Stata Statistical 
Software: Release 15 College Station, TX: StataCorp LP 
2017). Statistical analysis plans can be obtained from the 
first author (PKE).
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Discussion
In the current study, we will investigate the clinical effect 
of 3  g/day of adjunctive NAC treatment on symptoms 
of bipolar depression utilizing a randomized, double-
blinded, parallel group, placebo-controlled design. People 
diagnosed with bipolar disorder predominantly experi-
ence depression, which is currently challenging to treat 
(Grande et  al. 2016). It is evident that a large group of 
patients do not respond adequately to traditional phar-
macotherapy and/or psychotherapy, which creates a need 
for novel treatment opportunities. If this trial indicates 
that NAC treatment significantly reduces symptoms of 
depression, NAC may become an important part of the 
pharmacotherapeutical options for bipolar disorder.
NAC is well-tolerated with few and often mild adverse 
events (Fernandes et  al. 2016), and is available without 
prescription in many countries. The selected dosage in 
this trial has been well-tolerated in previous trials (Prado 
et al. 2015; Mardikian et al. 2007). NAC is hypothesized 
to decrease symptoms of depression at least in part due 
to its antioxidant properties. At present, few studies have 
investigated the effects of NAC in patients with bipolar 
depression, and the results have been mixed. Our study 
therefore will add to the limited clinical database (Berk 
et al. 2008, 2012).
The main strengths of the trial are the double-blinded 
design, with only two raters, and the possibility to do 
the study interviews in the patients’ home, which should 
reduce drop-outs.
To increase adherence, the study medication is for-
mulated as tablets instead of effervescent tablets, mak-
ing is possible to take it along with existing medication. 
To reflect usual clinical practice, all kinds of non-study 
pharmaceutical treatment are allowed, including changes 
prior to and after inclusion. However, this may diminish 
the chances to detect a potential superiority of NAC over 
placebo.
The novelty of this study is the collection of several bio-
logical materials to explore the oxidative balance, inflam-
mation and DNA damage related to the disorder and the 
treatment. Additionally, the study will shed light on the 
possible immune modulatory effects of NAC treatment. 
The markers may provide an insight to the potential 
mechanisms underlying the pathophysiology of BD.
Dissemination of results
The results from this study will be presented at national 
and international conferences and published in peer-
reviewed journals.
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